MoroccoTuberculosis profile
Population  2015 34 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.2 (0.043–13) 9.4 (0.13–37)
Mortality (HIV+TB only) 0.14 (0.044–0.3) 0.42 (0.13–0.88)
Incidence  (includes HIV+TB) 37 (34–40) 107 (98–117)
Incidence (HIV+TB only) 0.79 (0.63–0.96) 2.3 (1.8–2.8)
Incidence (MDR/RR-TB)** 0.58 (0.32–0.84) 1.7 (0.93–2.4)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 2 (1.4–2.7) 13 (10–16) 15 (11–19)
Males 2 (1.5–2.5) 20 (16–24) 22 (17–26)
Total 4 (3.3–4.7) 33 (31–35) 37 (34–40)
TB case notifications, 2015  
Total cases notified 31 403
Total new and relapse 30 636
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 47%
          - % pulmonary 53%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 83% (76–91)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0–0.35)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 316 2%
          - on antiretroviral therapy 316 100%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  330
(200–460)
Estimated % of TB cases with MDR/RR-TB 1% (0.3–1.7) 8.7% (4.8–13)  
% notified tested for rifampicin resistance   15% 2 820
MDR/RR-TB cases tested for resistance to second-line drugs   40
Laboratory-confirmed cases MDR/RR-TB: 164, XDR-TB: 6
Patients started on treatment **** MDR/RR-TB: 166, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 86% 29 992
Previously treated cases, excluding relapse, registered in 2014 63% 881
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 42% 65
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment 85%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 15
Funding source: 87% domestic, 13% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-06-24 Data: www.who.int/tb/data